About MGRC

As a leading genomics and biopharmaceutical company in Southeast Asia, Malaysian Genomics Resource Centre Bhd (MGRC) has pioneered genome sequencing, bioinformatics analysis, genetic screening services, and cancer immunotherapy in the region.

MGRC has an established track record of delivering on large-scale projects for the government of Malaysia, as well as local and international research centres, public institutes, academia and corporations from pharmaceutical and various other sectors. Some notable customers have included Novartis, Brigham & Women’s Hospital (of Harvard Medical School) and Washington University of Medicine, among others.

MGRC’s extensive experience in healthcare, especially in genomics, genetics and clinical diagnostics extends to translational medicine, which is the transferring of knowledge and technology from research domains to clinical use by doctors in clinics and hospitals. Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, MGRC is committed to improving access to the latest in precision and personalised healthcare solutions.

MGRC’s new facility consists of two state-of-the-art laboratories – a specialised cell processing laboratory and a molecular biology laboratory for genetics and genomics analysis. MGRC’s cell laboratory is the first privately owned Biosafety Level 2 (BSL-2) and Current Good Manufacturing Practice (CGMP) laboratory in Malaysia to produce CAR T-cells for solid cancer immunotherapy in the region, as well as stem cell production and other cell engineering services. The BSL-2 and CGMP laboratory certifications indicate that a facility follows a stringent set of biocontainment standards to protect laboratory personnel, the surrounding environment, and the community. MGRC has also obtained three ISO certifications under the Integrated Management System: ISO 9001:2015, ISO 15189:2014 and ISO 17025:2017.